Literature DB >> 32105604

Pre-arrayed Pan-AAV Peptide Display Libraries for Rapid Single-Round Screening.

Kathleen Börner1, Eike Kienle2, Lin-Ya Huang3, Jonas Weinmann4, Anna Sacher5, Philipp Bayer4, Christian Stüllein6, Julia Fakhiri4, Laura Zimmermann5, Adrian Westhaus4, Jürgen Beneke7, Nina Beil7, Ellen Wiedtke2, Carolin Schmelas4, Dominik Miltner4, Alexander Rau4, Holger Erfle7, Hans-Georg Kräusslich8, Martin Müller5, Mavis Agbandje-McKenna3, Dirk Grimm9.   

Abstract

Display of short peptides on the surface of adeno-associated viruses (AAVs) is a powerful technology for the generation of gene therapy vectors with altered cell specificities and/or transduction efficiencies. Following its extensive prior use in the best characterized AAV serotype 2 (AAV2), recent reports also indicate the potential of other AAV isolates as scaffolds for peptide display. In this study, we systematically explored the respective capacities of 13 different AAV capsid variants to tolerate 27 peptides inserted on the surface followed by production of reporter-encoding vectors. Single-round screening in pre-arrayed 96-well plates permitted rapid and simple identification of superior vectors in >90 cell types, including T cells and primary cells. Notably, vector performance depended not only on the combination of capsid, peptide, and cell type, but also on the position of the inserted peptide and the nature of flanking residues. For optimal data availability and accessibility, all results were assembled in a searchable online database offering multiple output styles. Finally, we established a reverse-transduction pipeline based on vector pre-spotting in 96- or 384-well plates that facilitates high-throughput library panning. Our comprehensive illustration of the vast potential of alternative AAV capsids for peptide display should accelerate their in vivo screening and application as unique gene therapy vectors.
Copyright © 2020 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32105604      PMCID: PMC7132618          DOI: 10.1016/j.ymthe.2020.02.009

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  54 in total

1.  Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes.

Authors:  Gregory S Arnold; A Kate Sasser; Matthew D Stachler; Jeffrey S Bartlett
Journal:  Mol Ther       Date:  2006-04-19       Impact factor: 11.454

2.  Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors.

Authors:  K Varadi; S Michelfelder; T Korff; M Hecker; M Trepel; H A Katus; J A Kleinschmidt; O J Müller
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

3.  Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy.

Authors:  Jessica Sallach; Giovanni Di Pasquale; Fernando Larcher; Nadine Niehoff; Matthias Rübsam; Anke Huber; Jay Chiorini; David Almarza; Sabine A Eming; Hikmet Ulus; Stephen Nishimura; Ulrich T Hacker; Michael Hallek; Carien M Niessen; Hildegard Büning
Journal:  Mol Ther       Date:  2014-01-28       Impact factor: 11.454

4.  In vitro selection of viral vectors with modified tropism: the adeno-associated virus display.

Authors:  Luca Perabo; Hildegard Büning; David M Kofler; Martin U Ried; Anne Girod; Clemens M Wendtner; Jörg Enssle; Michael Hallek
Journal:  Mol Ther       Date:  2003-07       Impact factor: 11.454

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

6.  RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism.

Authors:  Wenfang Shi; Jeffrey S Bartlett
Journal:  Mol Ther       Date:  2003-04       Impact factor: 11.454

7.  Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions.

Authors:  K White; H Büning; A Kritz; H Janicki; J McVey; L Perabo; G Murphy; M Odenthal; L M Work; M Hallek; S A Nicklin; A H Baker
Journal:  Gene Ther       Date:  2007-11-15       Impact factor: 5.250

8.  Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors.

Authors:  Oliver J Müller; Felix Kaul; Matthew D Weitzman; Renata Pasqualini; Wadih Arap; Jürgen A Kleinschmidt; Martin Trepel
Journal:  Nat Biotechnol       Date:  2003-08-03       Impact factor: 54.908

9.  Relevance of Assembly-Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein Stability in Mammalian and Insect Cells.

Authors:  Stefanie Grosse; Magalie Penaud-Budloo; Anne-Kathrin Herrmann; Kathleen Börner; Julia Fakhiri; Vibor Laketa; Chiara Krämer; Ellen Wiedtke; Manuel Gunkel; Lucie Ménard; Eduard Ayuso; Dirk Grimm
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

10.  Targeted Transgene Activation in the Brain Tissue by Systemic Delivery of Engineered AAV1 Expressing CRISPRa.

Authors:  Cia-Hin Lau; Jonathan Weng-Thim Ho; Pik Kwan Lo; Chung Tin
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-23
View more
  13 in total

1.  Identification of adeno-associated virus variants for gene transfer into human neural cell types by parallel capsid screening.

Authors:  Lea Jessica Flitsch; Kathleen Börner; Christian Stüllein; Simon Ziegler; Vera Sonntag-Buck; Ellen Wiedtke; Vesselina Semkova; Si Wah Christina Au Yeung; Julia Schlee; Mohamad Hajo; Mona Mathews; Beatrice Stefanie Ludwig; Susanne Kossatz; Horst Kessler; Dirk Grimm; Oliver Brüstle
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

Review 2.  Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.

Authors:  Julia Fakhiri; Dirk Grimm
Journal:  Mol Ther       Date:  2021-04-05       Impact factor: 11.454

3.  Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species.

Authors:  Mohammadsharif Tabebordbar; Kim A Lagerborg; Alexandra Stanton; Emily M King; Simon Ye; Liana Tellez; Allison Krunnfusz; Sahar Tavakoli; Jeffrey J Widrick; Kathleen A Messemer; Emily C Troiano; Behzad Moghadaszadeh; Bryan L Peacker; Krystynne A Leacock; Naftali Horwitz; Alan H Beggs; Amy J Wagers; Pardis C Sabeti
Journal:  Cell       Date:  2021-09-09       Impact factor: 66.850

4.  Molecular Signature of Astrocytes for Gene Delivery by the Synthetic Adeno-Associated Viral Vector rAAV9P1.

Authors:  Amelie Bauer; Matteo Puglisi; Dennis Nagl; Joel A Schick; Thomas Werner; Andreas Klingl; Jihad El Andari; Veit Hornung; Horst Kessler; Magdalena Götz; Dirk Grimm; Ruth Brack-Werner
Journal:  Adv Sci (Weinh)       Date:  2022-04-10       Impact factor: 17.521

5.  A universal protocol for isolating retinal ON bipolar cells across species via fluorescence-activated cell sorting.

Authors:  Elisa Murenu; Marina Pavlou; Lisa Richter; Kleopatra Rapti; Sabrina Just; Jasmina Cehajic-Kapetanovic; Neda Tafrishi; Andrew Hayes; Rachel Scholey; Robert Lucas; Hildegard Büning; Dirk Grimm; Stylianos Michalakis
Journal:  Mol Ther Methods Clin Dev       Date:  2021-01-26       Impact factor: 6.698

6.  Development of an AAV9-RNAi-mediated silencing strategy to abrogate TRPM4 expression in the adult heart.

Authors:  Rebekka Medert; Andreas Jungmann; Staffan Hildebrand; Martin Busch; Dirk Grimm; Veit Flockerzi; Oliver J Müller; Patrick Most; Dagmar Schumacher; Marc Freichel
Journal:  Pflugers Arch       Date:  2021-02-13       Impact factor: 3.657

7.  A comparison of AAV-vector production methods for gene therapy and preclinical assessment.

Authors:  Marcus Davidsson; Matilde Negrini; Swantje Hauser; Alexander Svanbergsson; Marcus Lockowandt; Giuseppe Tomasello; Fredric P Manfredsson; Andreas Heuer
Journal:  Sci Rep       Date:  2020-12-09       Impact factor: 4.379

8.  Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors.

Authors:  Jonas Becker; Megan Lynn Stanifer; Sarah Rebecca Leist; Bettina Stolp; Olena Maiakovska; Ande West; Ellen Wiedtke; Kathleen Börner; Ali Ghanem; Ina Ambiel; Longping Victor Tse; Oliver Till Fackler; Ralph Steven Baric; Steeve Boulant; Dirk Grimm
Journal:  Mol Ther       Date:  2022-01-14       Impact factor: 12.910

9.  Induction of Hepatitis E Virus Anti-ORF3 Antibodies from Systemic Administration of a Muscle-Specific Adeno-Associated Virus (AAV) Vector.

Authors:  Lars Maurer; Jihad El Andari; Kleopatra Rapti; Laura Spreyer; Eike Steinmann; Dirk Grimm; Viet Loan Dao Thi
Journal:  Viruses       Date:  2022-01-27       Impact factor: 5.048

Review 10.  Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.

Authors:  Karim Shalaby; Mustapha Aouida; Omar El-Agnaf
Journal:  Int J Mol Sci       Date:  2020-10-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.